We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03913481
Previous Study | Return to List | Next Study

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients. (ANH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03913481
Recruitment Status : Recruiting
First Posted : April 12, 2019
Last Update Posted : June 21, 2022
Information provided by (Responsible Party):
Giovanni Landoni, Università Vita-Salute San Raffaele

Brief Summary:

Transfusions are one of the most overused treatments in modern medicine, and saving blood is one important issue all around the world. Cardiac surgery makes up a large percentage of the overall blood components consumption in surgery.

Acute normovolemic hemo-dilution (ANH) is a well-known strategy which has been used for years without the support of high quality evidence based medicine to improve post-cardiopulmonary bypass coagulation and reduce red blood cells (RBC) transfusion. We designed a multicenter randomized controlled trial to investigate the effect of ANH in reducing the number of cardiac surgery patients receiving RBC transfusions during hospital stay. We will randomize 2000 patients to have sufficient power to demonstrate a 20% relative and 7% absolute risk reduction in the number of patients' RBC transfusion. If the results of the study will confirm our hypothesis, this will have a great impact on blood management in cardiac operating room.

Condition or disease Intervention/treatment Phase
C.Surgical Procedure; Cardiac Procedure: Acute normovolemic hemodilution Procedure: Standard care Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Acute Normovolemic Hemodilution in High-risk Cardiac Surgery Patients. A Multicentre Randomized Trial.
Actual Study Start Date : April 15, 2019
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : September 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Surgery

Arm Intervention/treatment
Experimental: ANH
Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.
Procedure: Acute normovolemic hemodilution
In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.

Standard care
Procedure: Standard care
Best available treatment without ANH

Primary Outcome Measures :
  1. RBCs transfusion [ Time Frame: hospital discharge, an average of 10 days ]
    The number of patients receiving RBCs transfusion after elective cardiac surgery.

Secondary Outcome Measures :
  1. Mortality [ Time Frame: 30 days ]
    30-day mortality

  2. Bleeding complications [ Time Frame: hospital discharge, an average of 10 days ]
    • Amount of blood components (RBC, fresh frozen plasma-FFP, platelet -PLT) transfused (units/ml)
    • Estimated total blood volume lost (ml) at 12 hours after surgery
    • Surgical revision for bleeding

  3. Ischemic complications [ Time Frame: hospital discharge,an average of 10 days ]
    • Myocardial infarction
    • Stroke
    • Thromboembolic events

  4. AKI [ Time Frame: hospital discharge, an average of 10 days ]
    Developing of acute kidney injury

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent
  • Any cardiac surgical intervention on CPB
  • Elective surgery

Exclusion Criteria:

  • Medical decision (e.g.: planned pre-CPB ANH considered undeniable for ethical reasons or not applicable for safety issues)
  • Unstable Coronary Artery Disease: Recent (< 6 weeks) myocardial infarction, unstable angina, severe (> 70%) left main coronary artery stenosis
  • Critical preoperative state (ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, hemodynamic instability, preoperative inotropes or IABP, preoperative severe acute renal failure (anuria or oliguria <10ml/hr.)
  • Emergency surgery
  • Pregnancy
  • Unfeasibility to withdraw ≥ 650 ml without inducing hemodynamic instability
  • Unfeasibility to withdraw ≥ 650 ml without inducing pre-CPB anemia (Htc <30%)
  • Unfeasibility to withdraw ≥ 650 ml without inducing low Htc during CPB (Htc <24%)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03913481

Layout table for location contacts
Contact: Giovanni Landoni, Prof +39022643 ext 6151 landoni.giovanni@hsr.it

Layout table for location information
Ospedale San Raffaele di Milano, Italy Recruiting
Milano, Milano, Italy, Italy, 20132
Contact: Giovanni Landoni, Prof         
Sub-Investigator: Fabrizio Monaco, MD         
Città di Lecce Hospital Recruiting
Lecce, Puglia, Italy
Contact: Giuseppe Santarpino, MD         
Maria Cecilia Hospital Recruiting
Cotignola, Ravenna, Italy
Contact: Lorenzo Mantovani, MD         
AOU Pisana Recruiting
Pisa, Italy
Contact: Fabio Guarracino, MD       f.guarracino@ao-pisa.toscana.it   
AOR San Carlo Recruiting
Potenza, Italy
Contact: Gianluca Paternoster         
Russian Federation
Astrakhan Centre For Cardiac Surgery Recruiting
Astrakhan, Russian Federation
Contact: Valery Pasyuga, MD         
State Research Institute of Circulation Pathology Recruiting
Novosibirsk, Russian Federation
Contact: Vladimir Lomivorotov         
Saint-Petersburg State University Hospital Recruiting
Saint Petersburg, Russian Federation
Contact: Sergey Efremov         
Saudi Arabia
King Abdullah Medical City Recruiting
Mecca, Saudi Arabia
Contact: Ahmed Galal Farag, MD         
Institute of Cardiovascular Diseases "Dedinje" Recruiting
Belgrade, Serbia
Contact: Miomir Jovic, MD         
Sub-Investigator: Gordana Gazivoda, MD         
National University Hospital Recruiting
Singapore, Singapore
Contact: Lian Kah Ti, MD         
Chiang Mai University Hospital Recruiting
Chiang Mai, Thailand
Contact: Suraphong Lorsomradee, MD         
Sponsors and Collaborators
Università Vita-Salute San Raffaele
Layout table for investigator information
Study Chair: Alberto Zangrillo, Prof Vita-Salute University of Milano
Layout table for additonal information
Responsible Party: Giovanni Landoni, MD, Associate Professor, Università Vita-Salute San Raffaele
ClinicalTrials.gov Identifier: NCT03913481    
Other Study ID Numbers: ANH/35/OSR
First Posted: April 12, 2019    Key Record Dates
Last Update Posted: June 21, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Giovanni Landoni, Università Vita-Salute San Raffaele:
organ and systemic injury responses to surgery
ischemia- reperfusion
including integrating pathways and signals
cardiac surgery